These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 26251521)

  • 1. Clinicopathological characteristics of RHOA mutations in a Central European gastric cancer cohort.
    Röcken C; Behrens HM; Böger C; Krüger S
    J Clin Pathol; 2016 Jan; 69(1):70-5. PubMed ID: 26251521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low incidence of KRAS, BRAF, and PIK3CA mutations in adenocarcinomas of the ampulla of Vater and their prognostic value.
    Kwon MJ; Kim JW; Jung JP; Cho JW; Nam ES; Cho SJ; Kim JS; Park HR; Min SK; Seo J; Min KW; Kim DH; Jeon JY
    Hum Pathol; 2016 Apr; 50():90-100. PubMed ID: 26997442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.
    Tabernero J; Lenz HJ; Siena S; Sobrero A; Falcone A; Ychou M; Humblet Y; Bouché O; Mineur L; Barone C; Adenis A; Yoshino T; Goldberg RM; Sargent DJ; Wagner A; Laurent D; Teufel M; Jeffers M; Grothey A; Van Cutsem E
    Lancet Oncol; 2015 Aug; 16(8):937-48. PubMed ID: 26184520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes.
    Sinicrope FA; Shi Q; Smyrk TC; Thibodeau SN; Dienstmann R; Guinney J; Bot BM; Tejpar S; Delorenzi M; Goldberg RM; Mahoney M; Sargent DJ; Alberts SR
    Gastroenterology; 2015 Jan; 148(1):88-99. PubMed ID: 25305506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased RhoA Activity Predicts Worse Overall Survival in Patients Undergoing Surgical Resection for Lauren Diffuse-Type Gastric Adenocarcinoma.
    Chang KK; Cho SJ; Yoon C; Lee JH; Park DJ; Yoon SS
    Ann Surg Oncol; 2016 Dec; 23(13):4238-4246. PubMed ID: 27364501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p53 immunostaining cannot be used to predict TP53 mutations in gastric cancer: results from a large Central European cohort.
    Schoop I; Maleki SS; Behrens HM; Krüger S; Haag J; Röcken C
    Hum Pathol; 2020 Nov; 105():53-66. PubMed ID: 32971129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer.
    He C; Bian XY; Ni XZ; Shen DP; Shen YY; Liu H; Shen ZY; Liu Q
    World J Gastroenterol; 2013; 19(14):2171-8. PubMed ID: 23599643
    [TBL] [Abstract][Full Text] [Related]  

  • 8. KRAS and PIK3CA mutations in colorectal adenocarcinomas correlate with aggressive histological features and behavior.
    Jang S; Hong M; Shin MK; Kim BC; Shin HS; Yu E; Hong SM; Kim J; Chun SM; Kim TI; Choi KC; Ko YW; Kim JW
    Hum Pathol; 2017 Jul; 65():21-30. PubMed ID: 28188750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genomic and Pathologic Profiling of Very Well-Differentiated Gastric Adenocarcinoma of Intestinal Type: A Study With Emphasis on Diffuse-Type Transformation.
    Rokutan H; Arai Y; Kunita A; Yamasaki S; Nakamura H; Hama N; Nakayama A; Hosoda F; Totoki Y; Fujishiro M; Seto Y; Shibata T; Ushiku T
    Am J Surg Pathol; 2024 Jun; 48(6):652-661. PubMed ID: 38584451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epstein-Barr virus-associated gastric cancer reveals intratumoral heterogeneity of PIK3CA mutations.
    Böger C; Krüger S; Behrens HM; Bock S; Haag J; Kalthoff H; Röcken C
    Ann Oncol; 2017 May; 28(5):1005-1014. PubMed ID: 28453696
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intratumoral heterogeneity and loss of ARID1A expression in gastric cancer correlates with increased PD-L1 expression in Western patients.
    Tober JM; Halske C; Behrens HM; Krüger S; Röcken C
    Hum Pathol; 2019 Dec; 94():98-109. PubMed ID: 31704366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RHOA mutation in diffuse-type gastric cancer: a comparative clinicopathology analysis of 87 cases.
    Ushiku T; Ishikawa S; Kakiuchi M; Tanaka A; Katoh H; Aburatani H; Lauwers GY; Fukayama M
    Gastric Cancer; 2016 Apr; 19(2):403-411. PubMed ID: 25823974
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutational analysis and clinical correlation of metastatic colorectal cancer.
    Russo AL; Borger DR; Szymonifka J; Ryan DP; Wo JY; Blaszkowsky LS; Kwak EL; Allen JN; Wadlow RC; Zhu AX; Murphy JE; Faris JE; Dias-Santagata D; Haigis KM; Ellisen LW; Iafrate AJ; Hong TS
    Cancer; 2014 May; 120(10):1482-90. PubMed ID: 24500602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gastric poorly cohesive carcinoma: a correlative study of mutational signatures and prognostic significance based on histopathological subtypes.
    Kwon CH; Kim YK; Lee S; Kim A; Park HJ; Choi Y; Won YJ; Park DY; Lauwers GY
    Histopathology; 2018 Mar; 72(4):556-568. PubMed ID: 28873240
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PIK3CA mutations in advanced cancers: characteristics and outcomes.
    Janku F; Wheler JJ; Naing A; Stepanek VM; Falchook GS; Fu S; Garrido-Laguna I; Tsimberidou AM; Piha-Paul SA; Moulder SL; Lee JJ; Luthra R; Hong DS; Kurzrock R
    Oncotarget; 2012 Dec; 3(12):1566-75. PubMed ID: 23248156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subtype-specific KRAS mutations in advanced lung adenocarcinoma: a retrospective study of patients treated with platinum-based chemotherapy.
    Cserepes M; Ostoros G; Lohinai Z; Raso E; Barbai T; Timar J; Rozsas A; Moldvay J; Kovalszky I; Fabian K; Gyulai M; Ghanim B; Laszlo V; Klikovits T; Hoda MA; Grusch M; Berger W; Klepetko W; Hegedus B; Dome B
    Eur J Cancer; 2014 Jul; 50(10):1819-1828. PubMed ID: 24768329
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Correlation Between RhoA Expression and Clinicopathological Characteristics in Gastric Cancer Patients After Curative Surgery.
    Huang KH; Lan YT; Chen MH; Chao Y; Lo SS; Li AF; Wu CW; Chiou SH; Yang MH; Shyr YM; Fang WL
    World J Surg; 2015 Sep; 39(9):2289-99. PubMed ID: 26013205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Colorectal poorly differentiated neuroendocrine carcinomas frequently exhibit BRAF mutations and are associated with poor overall survival.
    Olevian DC; Nikiforova MN; Chiosea S; Sun W; Bahary N; Kuan SF; Pai RK
    Hum Pathol; 2016 Mar; 49():124-34. PubMed ID: 26826419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Are PIK3CA Mutation and Amplification Associated with Clinicopathological Characteristics of Gastric Cancer?
    Lee H; Hwang IS; Choi IJ; Kang YN; Park KU; Lee JH
    Asian Pac J Cancer Prev; 2015; 16(11):4493-6. PubMed ID: 26107192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. KRAS, NRAS, PIK3CA exon 20, and BRAF genotypes in synchronous and metachronous primary colorectal cancers diagnostic and therapeutic implications.
    Balschun K; Haag J; Wenke AK; von Schönfels W; Schwarz NT; Röcken C
    J Mol Diagn; 2011 Jul; 13(4):436-45. PubMed ID: 21704278
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.